The high glycolytic capacity demonstrated by stem cell-like CD133/PROM1HIGH cells was attributed to significantly enhanced mRNA transcript levels of glycolytic enzymes (ALDOA: p < 0.05, ENO1: p < 0.05, PKM2: p < 0.01; SLC2A1: p < 0.05, LDH: p < 0.05), indicating that high expression of glycolytic enzymes may correspond with increased stemness in GBM tumors (Additional file 1: Figure 2B). Here, SLC2A1 is linked to glioblastoma.